Skip to main content
Fig. 1 | Substance Abuse Treatment, Prevention, and Policy

Fig. 1

From: Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017

Fig. 1

Estimated HCV treatment uptake in Norway and Sweden among OAT patients from 2014 to 2017. HCV = hepatitis C virus infection, OAT = opioid agonist therapy. Sources OAT and HCV treatment: The Swedish Prescribed Drug Register (SPDR), The Norwegian Prescription Database (NorPD). Prevalence: Intro-HCV = Integrated treatment of hepatitis C study, Kåberg et al. [24]: Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program, Micallef et al. [27]: Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. For more comprehensive details on sources and model calculation, see additional file 1.

Back to article page